Not so much about viability but more about priority. Terms like low hanging fruit come to mind. They’ll tackle the one that best balances objectives like ease of execution (e.g. recruitment), time and cost to execute, commercial value, partnership potential, patient need, etc.
- Forums
- ASX - By Stock
- RAC
- Ann: Zantrene Improves Immune Therapy Treatment of Melanoma
Ann: Zantrene Improves Immune Therapy Treatment of Melanoma, page-56
-
- There are more pages in this discussion • 36 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
|
|||||
Last
$1.75 |
Change
0.010(0.57%) |
Mkt cap ! $298.0M |
Open | High | Low | Value | Volume |
$1.73 | $1.83 | $1.73 | $272.0K | 152.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 9998 | $1.75 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.79 | 2000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 9998 | 1.750 |
1 | 7599 | 1.730 |
1 | 581 | 1.720 |
3 | 11557 | 1.710 |
4 | 46280 | 1.700 |
Price($) | Vol. | No. |
---|---|---|
1.790 | 2000 | 1 |
1.830 | 44030 | 2 |
1.840 | 10500 | 2 |
1.850 | 14500 | 3 |
1.860 | 949 | 2 |
Last trade - 16.10pm 09/07/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |